Friday, December 5, 2025, Orlando, Florida, 7:00 PM – 9:00 PM Eastern Time

Expert Second Opinion: Investigators Discuss the Role of Novel Treatment Approaches in the Care of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

A CME-Accredited Friday Satellite Symposium Preceding the 67th ASH Annual Meeting

Register for in-person Register for webcast

 

Program Schedule — Eastern Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Location
Hyatt Regency Orlando
9801 International Drive
Orlando, Florida

Meeting Room
Regency Ballroom TUV (Convention Level)

There is no registration fee for this event. For the in-person symposium in Orlando, preregistration is required as seating is limited.  
 
Faculty
Nancy L Bartlett, MD
Professor of Medicine
Koman Chair in Medical Oncology
Washington University School of Medicine
St Louis, Missouri

John P Leonard, MD
Laura and Isaac Perlmutter Professor of Hematology and Medical Oncology
Director, Division of Hematology
and Medical Oncology
Director, Center for Blood Cancers
Senior Advisor to the Dean/CEO and Chief Clinical Officer for Enterprise Cancer Strategy
and Operations
Interim Director, Laura and Isaac Perlmutter Cancer Center
NYU Grossman School of Medicine
NYU Langone Health
New York, New York

Matthew Matasar, MD
Chief, Division of Blood Disorders
Rutgers Cancer Institute
Hematologist/Oncologist
Professor
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey


Loretta J Nastoupil, MD
Oncologist
Southwest Oncology
CommonSpirit Mercy Hospital
Durango, Colorado

Professor Pier Luigi Zinzani
Professor of Hematology
Alma Mater Studiorum — University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Moderator
Neil Love, MD
Research To Practice
Miami, Florida



This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, and Pfizer Inc.
Program Schedule — Eastern Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Rational Incorporation of Antibody-Drug Conjugates into the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Matasar

  • Key factors guiding the selection of initial therapy for patients with DLBCL
  • Extended follow-up from the Phase III POLARIX trial comparing polatuzumab vedotin/R-CHP to R-CHOP for patients with previously untreated DLBCL; clinical activity observed with polatuzumab vedotin/R-CHP in various patient subsets
  • Tolerability profiles of polatuzumab vedotin/R-CHP and R-CHOP in the POLARIX trial
  • Appropriate selection of candidates to receive polatuzumab vedotin as a component of up-front therapy for DLBCL
  • Initial safety data from the Phase III POLAR BEAR trial comparing polatuzumab vedotin with R-mini-CHP to R-mini-CHOP for older or frail patients with treatment-naïve DLBCL; anticipated read-out of full results

MODULE 2: Clinical Utility of CD19-Directed Monoclonal Antibodies for DLBCL and Follicular Lymphoma (FL) — Dr Leonard

  • Extended follow-up from the Phase II L-MIND study supporting the use of tafasitamab/lenalidomide for relapsed/refractory (R/R) DLBCL; optimal sequencing of this strategy for individual patients
  • Ongoing confirmatory Phase III firmMIND trial of tafasitamab/lenalidomide for patients with R/R DLBCL; estimated completion date
  • Biological rationale for the evaluation of tafasitamab in the treatment of FL
  • Design, eligibility criteria and key efficacy and safety findings from the Phase III inMIND trial evaluating the addition of tafasitamab to lenalidomide/rituximab (R2) for R/R FL or marginal zone lymphoma
  • Recent FDA approval and optimal sequencing of tafasitamab/R2 for patients with R/R FL
  • Tolerability profile of tafasitamab-based combination therapy; optimal monitoring for and management of adverse events

MODULE 3: Optimal Use of Antibody-Drug Conjugates in the Treatment of R/R DLBCL — Prof Zinzani

  • Efficacy and safety findings from the Phase III POLARGO study of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin for patients with R/R DLBCL; potential role of this regimen
  • Extended follow-up from the Phase II LOTIS-2 study supporting the use of loncastuximab tesirine for patients with R/R DLBCL
  • Optimal sequencing of loncastuximab tesirine for individual patients with R/R DLBCL
  • Initial results from the Phase Ib LOTIS-7 study of loncastuximab tesirine in combination with glofitamab for R/R DLBCL; implications for clinical practice and ongoing research
  • Available data with loncastuximab tesirine in other subtypes of non-Hodgkin lymphoma (NHL)
  • Recent NCCN guideline inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL
  • Key efficacy and safety findings from the Phase III ECHELON-3 study evaluating brentuximab vedotin combined with R2 for R/R DLBCL; outcomes for patients with CD30-positive and CD30-negative disease
  • Recent FDA approval and current clinical role of brentuximab vedotin for DLBCL

MODULE 4: Bispecific Antibody Therapy for DLBCL — Dr Bartlett

  • Pharmacologic similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for NHL; implications for efficacy, tolerability and ease of use
  • Key efficacy and safety outcomes from pivotal studies of monotherapy with the bispecific antibodies glofitamab and epcoritamab for R/R DLBCL
  • FDA approvals of glofitamab and epcoritamab; evidence-based sequencing of and selection between these agents for R/R DLBCL
  • Available research findings with bispecific antibodies in combination with other anticancer therapies and/or in earlier settings in therapy for DLBCL
  • Ongoing Phase III studies evaluating bispecific antibody-containing front-line regimens, such as glofitamab with polatuzumab vedotin/R-CHP and epcoritamab with R-CHOP, for patients with DLBCL

MODULE 5: Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes — Dr Nastoupil

  • Available data establishing the efficacy and safety of mosunetuzumab and of epcoritamab as monotherapy for patients with R/R FL
  • FDA approval of mosunetuzumab and epcoritamab monotherapy for patients with FL after 2 or more lines of systemic therapy; optimal incorporation in light of other treatment options
  • Emerging outcomes from the Phase III EPCORE FL-1 study supporting the recent FDA approval of epcoritamab in combination with R2 for patients with R/R FL
  • Available research findings with and ongoing studies of other bispecific antibody-based combination regimens for FL, including in the first-line setting
  • Available data with, ongoing investigation of and potential clinical role for bispecific antibodies in other NHL subtypes, such as mantle cell lymphoma and marginal zone lymphoma

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Identify patients with newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy would be appropriate.
  • Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies in combination with immunomodulatory agents for DLBCL and follicular lymphoma (FL), and use this information in patient-education discussions.
  • Appraise available research findings with and the current clinical role of CD19-targeted antibody-drug conjugates for patients with R/R DLBCL and FL.
  • Understand the biological rationale for, available research findings with and current clinical role of CD30-targeted antibody-drug conjugate-based therapy for patients with R/R DLBCL.
  • Consider published and emerging research data with and the current clinical role of CD20 x CD3 bispecific antibodies for patients with R/R DLBCL and FL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with novel therapies commonly used in the care of patients with DLBCL and FL.
  • Recall new data with agents and strategies currently under investigation for DLBCL and FL, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Bartlett — Advisory Committees: AbbVie Inc, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Pfizer Inc, Seagen Inc; Contracted Research: AbbVie Inc, ADC Therapeutics, Autolus, Bristol Myers Squibb, Celgene Corporation, Forty Seven Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Kite, A Gilead Company, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Takeda Pharmaceuticals USA Inc. Dr Leonard — Consulting Agreements: AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Caribou Biosciences Inc, Eisai Inc, Foresight Diagnostics, Genentech, a member of the Roche Group, Grail Inc, Kyowa Kirin Co Ltd, Novartis, Ono Pharmaceutical Co Ltd, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sail Biomedicines, Teva Pharmaceutical Industries Ltd, Treeline Biosciences; Contracted Research: Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc; Data and Safety Monitoring Boards/Committees: BeOne, Genentech, a member of the Roche Group; Stock Options — Private Companies: Treeline Biosciences. Dr Matasar — Advisory Committees: Allogene Therapeutics, Arvinas, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Merck; Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Genentech, a member of the Roche Group, Janssen Biotech Inc, Pfizer Inc, Roche Laboratories Inc; Honoraria and Stipends: ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, Regeneron Pharmaceuticals Inc; Stock Ownership — Public Companies: Merck. Dr Nastoupil — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Genentech, a member of the Roche Group; Contracted Research: BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Genentech, a member of the Roche Group. Prof Zinzani — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Kyowa Kirin Co Ltd, Novartis, Recordati, Roche Laboratories Inc, Sobi, Takeda; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Kyowa Kirin Co Ltd, Merck, Novartis, Recordati, Roche Laboratories Inc, Sobi, Takeda.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, and Pfizer Inc.

Hyatt Regency Orlando
9801 International Drive
Orlando, FL 32819
+1 407 284 1234

Meeting Room
Regency Ballroom TUV (Convention Level)

Directions
The Hyatt Regency Orlando hotel is connected by pedestrian bridges to the Orange County Convention Center, where the ASH Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

There is no registration fee for this event. For the in-person symposium in Orlando, preregistration (below) is required as seating is limited for this program.

NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting.

Thank you for your interest in our CME program. At this time online registration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:30 PM ET on Friday, December 5th. If you are interested in attending, please visit the registration desk outside the Regency Ballroom TUV (Convention Level) of the Hyatt Regency Orlando hotel (9801 International Drive).
 
Hyatt Regency Orlando is conveniently connected by pedestrian bridge to the Orange County Convention Center, where the 67th ASH Annual Meeting is taking place.
  
If you have any questions, please feel free to contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
 
NOTICE:
Registration for this event is independent of registration for the ASH Annual Meeting and Exposition.
 
WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.